Moriko Ito

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.

Journal: Oncotarget

Published: June 17, 2019

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.

A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression.

Journal: PloS one

Published: April 10, 2019

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Journal: Cancer cell

Published: August 02, 2016

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Journal: eLife

Published: July 04, 2016

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.

Journal: Leukemia

Published: June 15, 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Journal: Cancer cell

Published: December 14, 2015

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Journal: Molecular cancer therapeutics

Published: May 26, 2015

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.

Journal: eLife

Published: January 15, 2015

T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia.

T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia.

Journal: Transfusion medicine (Oxford, England)

Published: April 01, 2014

Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.

Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.

Journal: PloS one

Published: June 18, 2013

CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.

CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.

Journal: Cell death & disease

Published: October 05, 2012

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

Journal: Cancer discovery

Published: September 25, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026